AIMS: The aim of this study was to evaluate the effect of rifampicin co-administration on the pharmacokinetics of ruboxistaurin and its active metabolite, N-desmethyl ruboxistaurin and, in addition, to compare the changes in pharmacokinetics of ruboxistaurin and N-desmethyl ruboxistaurin with the urinary 6beta-hydroxycortisol : cortisol ratio. Ruboxistaurin is a specific protein-kinase-C beta inhibitor in clinical development for the treatment of diabetic microvascular complications. METHODS: This was a two-period, one-sequence study. Sixteen healthy male subjects completed both study periods. In period one, a single 64 mg oral dose of ruboxistaurin was administered. In period two, 600 mg rifampicin was administered daily for 9 days, during which another single 64 mg ruboxistaurin dose was administered on day 7. Blood samples were collected and assayed for ruboxistaurin and N-desmethyl ruboxistaurin. CYP3A4 induction was assessed by ratios of urinary 6beta-hydroxycortisol : cortisol (6beta-OHC : C) obtained via 24 h and morning-spot sampling techniques. Results Following repeated doses of rifampicin, both the mean C(max) and AUC(0,infinity) of ruboxistaurin were significantly reduced by approximately 95% (P < or = 0.001). For the metabolite, the mean C(max) decreased by 68% (P < or = 0.001), and AUC(0,infinity) decreased by 77% (P < or = 0.001). The t(max) values did not appear affected. The 6beta-OHC : C ratios from both 24 h and morning spot methods increased significantly, consistent with CYP3A4 induction. CONCLUSIONS: The effect of rifampicin co-administration on the exposure of ruboxistaurin is consistent with ruboxistaurin being a substrate of CYP3A4. Therefore, co-administration with known CYP3A4 inducing agents (rifampicin, carbamazepine, phenobarbital, etc.) may decrease the concentrations of ruboxistaurin and N-desmethyl-ruboxistaurin. In this study, 6beta OHC : C ratios substantially underestimated the impact of rifampicin on ruboxistaurin.
AIMS: The aim of this study was to evaluate the effect of rifampicin co-administration on the pharmacokinetics of ruboxistaurin and its active metabolite, N-desmethyl ruboxistaurin and, in addition, to compare the changes in pharmacokinetics of ruboxistaurin and N-desmethyl ruboxistaurin with the urinary 6beta-hydroxycortisol : cortisol ratio. Ruboxistaurin is a specific protein-kinase-C beta inhibitor in clinical development for the treatment of diabetic microvascular complications. METHODS: This was a two-period, one-sequence study. Sixteen healthy male subjects completed both study periods. In period one, a single 64 mg oral dose of ruboxistaurin was administered. In period two, 600 mg rifampicin was administered daily for 9 days, during which another single 64 mg ruboxistaurin dose was administered on day 7. Blood samples were collected and assayed for ruboxistaurin and N-desmethyl ruboxistaurin. CYP3A4 induction was assessed by ratios of urinary 6beta-hydroxycortisol : cortisol (6beta-OHC : C) obtained via 24 h and morning-spot sampling techniques. Results Following repeated doses of rifampicin, both the mean C(max) and AUC(0,infinity) of ruboxistaurin were significantly reduced by approximately 95% (P < or = 0.001). For the metabolite, the mean C(max) decreased by 68% (P < or = 0.001), and AUC(0,infinity) decreased by 77% (P < or = 0.001). The t(max) values did not appear affected. The 6beta-OHC : C ratios from both 24 h and morning spot methods increased significantly, consistent with CYP3A4 induction. CONCLUSIONS: The effect of rifampicin co-administration on the exposure of ruboxistaurin is consistent with ruboxistaurin being a substrate of CYP3A4. Therefore, co-administration with known CYP3A4 inducing agents (rifampicin, carbamazepine, phenobarbital, etc.) may decrease the concentrations of ruboxistaurin and N-desmethyl-ruboxistaurin. In this study, 6beta OHC : C ratios substantially underestimated the impact of rifampicin on ruboxistaurin.
Authors: R B Kim; C Wandel; B Leake; M Cvetkovic; M F Fromm; P J Dempsey; M M Roden; F Belas; A K Chaudhary; D M Roden; A J Wood; G R Wilkinson Journal: Pharm Res Date: 1999-03 Impact factor: 4.200
Authors: L P Aiello; S E Bursell; A Clermont; E Duh; H Ishii; C Takagi; F Mori; T A Ciulla; K Ways; M Jirousek; L E Smith; G L King Journal: Diabetes Date: 1997-09 Impact factor: 9.461
Authors: M R Jirousek; J R Gillig; C M Gonzalez; W F Heath; J H McDonald; D A Neel; C J Rito; U Singh; L E Stramm; A Melikian-Badalian; M Baevsky; L M Ballas; S E Hall; L L Winneroski; M M Faul Journal: J Med Chem Date: 1996-07-05 Impact factor: 7.446
Authors: K Westphal; A Weinbrenner; M Zschiesche; G Franke; M Knoke; R Oertel; P Fritz; O von Richter; R Warzok; T Hachenberg; H M Kauffmann; D Schrenk; B Terhaag; H K Kroemer; W Siegmund Journal: Clin Pharmacol Ther Date: 2000-10 Impact factor: 6.875
Authors: M T Kinirons; D O'Shea; R B Kim; J D Groopman; K E Thummel; A J Wood; G R Wilkinson Journal: Clin Pharmacol Ther Date: 1999-09 Impact factor: 6.875
Authors: M F Paine; D D Shen; K L Kunze; J D Perkins; C L Marsh; J P McVicar; D M Barr; B S Gillies; K E Thummel Journal: Clin Pharmacol Ther Date: 1996-07 Impact factor: 6.875
Authors: Thomas E Sharp; Hajime Kubo; Remus M Berretta; Timothy Starosta; Markus Wallner; Giana J Schena; Alexander R Hobby; Daohai Yu; Danielle M Trappanese; Jon C George; Jeffery D Molkentin; Steven R Houser Journal: JACC Basic Transl Sci Date: 2017-12-25
Authors: Rehab A Alshammari; Fadilah S Aleanizy; Amal Aldarwesh; Fulwah Y Alqahtani; Wael A Mahdi; Bushra Alquadeib; Qamraa H Alqahtani; Nazrul Haq; Faiyaz Shakeel; Hosam G Abdelhady; Ibrahim A Alsarra Journal: Pharmaceutics Date: 2022-07-11 Impact factor: 6.525
Authors: Ehab S Eldesoky; Sherif I Kamel; Ahlam M Farghaly; Madiha Y Bakheet; Mohsen A Hedaya; Jean-Pascal Siest Journal: Biomark Insights Date: 2007-02-07